Try

Beam Therapeutics Inc.

BEAMUnited States

26 filed reports · 331 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

26 reports · Mar 2020 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR202,876Mar 2020 to Jun 2026
Annual · 10-KSEC EDGAR62,251Dec 2020 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 4, 2026301Open
FY2026 Q110-QMar 31, 2026May 7, 2026182Open
FY202510-KDec 31, 2025Feb 24, 2026688Open
FY2025 Q310-QSep 30, 2025Nov 4, 2025195Open
FY2025 Q210-QJun 30, 2025Aug 5, 2025115Open
FY2025 Q110-QMar 31, 2025May 6, 2025120Open
FY202410-KDec 31, 2024Feb 25, 2025350Open
FY2024 Q310-QSep 30, 2024Nov 5, 2024124Open
FY2024 Q210-QJun 30, 2024Aug 6, 2024105Open
FY2024 Q110-QMar 31, 2024May 7, 2024112Open
FY202310-KDec 31, 2023Feb 27, 2024340Open
FY2023 Q310-QSep 30, 2023Nov 8, 2023138Open

Financial data

331 concepts · 5,127 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial327 concepts · 5,063 facts · Dec 2018 to Jul 2026

  • Allocated share based compensation expense37 · Mar 2019 to Jun 2026
  • Capital expenditures incurred but not yet paid37 · Mar 2019 to Jun 2026
  • Cash and cash equivalents at carrying value37 · Mar 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents37 · Mar 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect37 · Mar 2019 to Jun 2026
  • Change in operating lease right-of-use assets37 · Mar 2019 to Jun 2026
  • Comprehensive income net of tax37 · Mar 2019 to Jun 2026
  • Depreciation37 · Mar 2019 to Jun 2026
  • Derivative gain loss on derivative net37 · Mar 2019 to Jun 2026
  • General and administrative expense (US GAAP)37 · Mar 2019 to Jun 2026
  • Increase decrease in accounts payable37 · Mar 2019 to Jun 2026
  • Increase decrease in accrued liabilities and other operating liabilities37 · Mar 2019 to Jun 2026
  • Increase decrease in other noncurrent liabilities37 · Mar 2019 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets37 · Mar 2019 to Jun 2026
  • Net cash provided by used in financing activities37 · Mar 2019 to Jun 2026
  • Net cash provided by used in investing activities37 · Mar 2019 to Jun 2026
  • Net cash provided by used in operating activities37 · Mar 2019 to Jun 2026
  • Net income loss37 · Mar 2019 to Jun 2026
  • Net income loss available to common stockholders basic37 · Mar 2019 to Jun 2026
  • Operating expenses (US GAAP)37 · Mar 2019 to Jun 2026
  • Operating income loss37 · Mar 2019 to Jun 2026
  • Payments to acquire property plant and equipment37 · Mar 2019 to Jun 2026
  • Proceeds from stock options exercised37 · Mar 2019 to Jun 2026
  • Profit loss37 · Mar 2019 to Jun 2026

Segment2 concepts · 56 facts · Dec 2022 to Jun 2026

  • General and administrative expense (US GAAP)28 · Dec 2022 to Jun 2026
  • Research and development expense28 · Dec 2022 to Jun 2026

Geography2 concepts · 8 facts · Dec 2020 to Dec 2025

  • Federal6 · Dec 2020 to Dec 2025
  • Income tax credits and adjustments2 · Dec 2020 to Dec 2021

Segments

64 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments3 members · 56 facts

  • Employee Related Expenses28 · Dec 2022 to Jun 2026
  • External General And Administrative Expenses14 · Dec 2022 to Jun 2026
  • External Research And Development Expenses14 · Dec 2022 to Jun 2026

Statement geographical1 member · 8 facts

  • MA8 · Dec 2020 to Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Beam Therapeutics Inc. (BEAM) data · FactIQ